| Dr C Steven Kocks, OD | |
|
1885 N Center Rd, Saginaw, MI 48638-5565 | |
| (989) 792-8686 | |
| (989) 792-8382 |
| Full Name | Dr C Steven Kocks |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 38 Years |
| Location | 1885 N Center Rd, Saginaw, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134114531 | NPI | - | NPPES |
| 490100 3083 | Other | MI | STATE LICENSE NUMBER |
| 01000819 | Other | MI | HEALTH PLUS |
| 4742203 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 490100 3083 (Michigan) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associates In Eyecare Plc | 3173564952 | 3 |
News Archive
Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a settlement agreement with Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc., a Canadian federal corporation; Biocad Médical Inc., a Quebec provincial corporation; Nobel Biocare USA, LLC, a Delaware limited liability company; and Nobel Biocare Procera, LLC, a Delaware limited liability company; (collectively "Nobel Entities") pursuant to which it settled civil actions in the United States, Canada, Italy and Germany involving the Nobel Entities and Sinblab.
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX).
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).
The current study published on the preprint server bioRxiv aims to understand how these compounds affect SARS-CoV-2 in vitro. The researchers from Aarhus University in Denmark examined 11 natural PEIs, with a single synthetic analog, screening them for inhibitory activity against the CPE of SARS-CoV-2 infecting cultured cells with overexpression of TMPRSS2, a serine protease that is instrumental in cleaving the spike protein of the virus.
› Verified 8 days ago
| Provider Name | Associates In Eyecare Plc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1174637565 PECOS PAC ID: 3173564952 Enrollment ID: O20050523000263 |
News Archive
Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a settlement agreement with Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc., a Canadian federal corporation; Biocad Médical Inc., a Quebec provincial corporation; Nobel Biocare USA, LLC, a Delaware limited liability company; and Nobel Biocare Procera, LLC, a Delaware limited liability company; (collectively "Nobel Entities") pursuant to which it settled civil actions in the United States, Canada, Italy and Germany involving the Nobel Entities and Sinblab.
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX).
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).
The current study published on the preprint server bioRxiv aims to understand how these compounds affect SARS-CoV-2 in vitro. The researchers from Aarhus University in Denmark examined 11 natural PEIs, with a single synthetic analog, screening them for inhibitory activity against the CPE of SARS-CoV-2 infecting cultured cells with overexpression of TMPRSS2, a serine protease that is instrumental in cleaving the spike protein of the virus.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr C Steven Kocks, OD 5319 Oakbrook Dr, Saginaw, MI 48603-8617 Ph: (989) 793-9383 | Dr C Steven Kocks, OD 1885 N Center Rd, Saginaw, MI 48638-5565 Ph: (989) 792-8686 |
News Archive
Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a settlement agreement with Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc., a Canadian federal corporation; Biocad Médical Inc., a Quebec provincial corporation; Nobel Biocare USA, LLC, a Delaware limited liability company; and Nobel Biocare Procera, LLC, a Delaware limited liability company; (collectively "Nobel Entities") pursuant to which it settled civil actions in the United States, Canada, Italy and Germany involving the Nobel Entities and Sinblab.
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX).
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).
The current study published on the preprint server bioRxiv aims to understand how these compounds affect SARS-CoV-2 in vitro. The researchers from Aarhus University in Denmark examined 11 natural PEIs, with a single synthetic analog, screening them for inhibitory activity against the CPE of SARS-CoV-2 infecting cultured cells with overexpression of TMPRSS2, a serine protease that is instrumental in cleaving the spike protein of the virus.
› Verified 8 days ago
Patrick J Bell, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: Great Lakes Eye Institute, 2393 Schust Rd, Saginaw, MI 48603 Phone: 989-793-2820 Fax: 989-793-9132 | |
Richard Hackman, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3275 Tittabawassee Rd, Saginaw, MI 48604 Phone: 989-399-3477 Fax: 989-399-3478 | |
Justin Moyer, Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3275 Tittabawassee Rd, Saginaw, MI 48604 Phone: 989-399-3477 | |
Riverfront Optical Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3200 Cabaret Trl S, Saginaw, MI 48603 Phone: 989-790-5005 Fax: 989-790-9179 | |
West Point Optical Group Optometrist Medicare: Not Enrolled in Medicare Practice Location: 4865 Fashion Square Mall, Saginaw, MI 48604 Phone: 989-793-8267 | |
Great Lakes Eye Institute Optometrist Medicare: Medicare Enrolled Practice Location: 2393 Schust Rd, Saginaw, MI 48603 Phone: 989-793-2820 Fax: 989-793-9132 | |
Dr. Joseph K Douglas, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 5025 Shattuck Rd, Saginaw, MI 48603 Phone: 989-752-7121 Fax: 989-752-6918 |